nach oben

Targeted Oncology

Erschienen in:

01.03.2014 | Day-to-Day Practice

Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature

verfasst von: Amaury Daste, Marine Gross-Goupil, Sophie Roca, Jean-Christophe Bernhard, Alain Ravaud

Erschienen in: Targeted Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Treatment of metastatic renal cell carcinoma has radically changed during the last decade with the approval of new drugs, antiangiogenic agents and mammalian targets of rapamycin (m-TOR) inhibitors. The outcome of metastatic clear-cell carcinoma has been significantly improved, while other entities such as metastatic papillary renal cell carcinoma are still associated with a poor prognosis. To date, there is no standard guideline for metastatic non clear cell carcinoma. We report the case of a 68-year-old patient with a pulmonary metastatic evolution of a papillary kidney cancer who has had more than 3 years disease progression-free survival and is under ongoing treatment with m-TOR inhibitors.

Linehan WM, Pinto PA, Srinivasan R et al (2007) Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13:671s–679sPubMedCrossRef

Ronnen EA, Kondagunta GV, Ishill N et al (2006) Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 107:2617–2621PubMedCrossRef

Steffens S, Janssen M, Roos FC et al (2012) Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma—a multicentre study. Eur J Cancer 48:2347–2352PubMedCrossRef

Motzer RJ, Bacik J, Mariani T et al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376–2381PubMedCrossRef

Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRef

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef

Escudier B, Pluzanska A, Korlewski P et al (2007) Bevacizumab plusinterferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, double-blind phase III trial. Lancet 370:2103–2111PubMedCrossRef

Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef

Escudier B, Kataja V (2010) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up on behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v137–9PubMedCrossRef

10.

Motzer RJ, Escudier B, Oudard S (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 15:116

11.

Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463PubMedCrossRef

12.

Choueri T, Plantade A, Elson P et al (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127–131CrossRef

13.

Dutcher JP, de Souza P, McDermott D et al (2009) Effect of temsirolimus versus interferon-a on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26:202–209PubMedCrossRef

14.

Escudier B, Bracarda S, Maroto JP et al (2012) Open-label phaseII trial of first-line everolimus monotherapy in patients with advanced papillary renal cell carcinoma: raptor interim analysis. Ann Oncol 23:9s, ix264

15.

Ravaud A, Oudard S, De-Fromont M et al (2012) First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). Ann Oncol 23:9s, ix263CrossRef

16.

Clinicaltrials.gov (2012). Everolimus versus sunitinib in non-clear cell renal cell carcinoma. Available at: http://www.clinicaltrials.gov/ct/show/NCT01185366. Accessed: July 24, 2012

17.

Clinicaltrials.gov. (2012) Phase II study of afinitor vs. sutent in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). Available at: http://www.clinicaltrials.gov/ct/show/NCT01108445. Accessed: July 24, 2012

18.

Chaux A, Schultz L, Albadine R et al (2012) Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol 43:2129–37PubMedCrossRef

19.

Srinivasan R, Linehan WM, Vaishampayan U et al (2009) A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 27:15s, suppl,abstr 5103CrossRef

Titel: Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature
verfasst von: Amaury Daste
Marine Gross-Goupil
Sophie Roca
Jean-Christophe Bernhard
Alain Ravaud
Publikationsdatum: 01.03.2014
Verlag: Springer International Publishing
Erschienen in: Targeted Oncology / Ausgabe 1/2014
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-012-0245-6

Neu im Fachgebiet Onkologie

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature

Abstract

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma

Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin

Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Trends in cancer-targeted antibody–drug conjugates

Caffeic acid phenylethyl ester and MG132, two novel nonconventional chemotherapeutic agents, induce apoptosis of human leukemic cells by disrupting mitochondrial function

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie